PRAXIS PRAX AIDS DRUG TO GO INTO WIDER TESTS NEW YORK April Praxis Pharmaceuticals Inc which owns worldwide licensing rights to the promising AIDS treatment AL said large scale tests of the drug are planned for this summer in the United States Arnold Lippa Praxis president said Praxis will test the drug in a few hundred patients with full blown AIDS in those with AIDS related complex a precursor to AIDS and in more patients with swollen lymph glands but no other AIDS symptoms Praxis reported a net loss of dlrs for the year ended June Lippa said the firm has about two mln dlrs left from its public offering in January But Lippa expects to easily spend five to mln dlrs in these new clinical trials He said the Beverly Hills Calif based company is preparing a private offering and discussing ventures with other pharmaceutical firms to help finance the cost of the trials As another mark of the interest in AL Anthony S Fauci who heads the National Institute of Allergy and Infectious Disease said the government will begin testing AL in its AIDS treatment evaluation units in June A spokeswoman said the study will be small and will establish the drug s toxicity She said the study will be expedited to allow the next phase of testing to proceed rapidly These plans follow the completion of a small scale test of the drug s effectiveness in eight patients with AIDS related lymphadenopathy swollen lymph glands at St Lukes Roosevelt Hospital in New York and another study of AIDS patients in Israel where the drug was developed Reuter